CD47 and cancer: Several clinical trials have commenced to assess the safety and tolerance of different doses of CGs in cancer patients (NCT02212639, NCT00017446, NCT02530398, NCT04621669, and NCT05828303), including the pharmacokinetic data of CGs in these patients concurrently receiving other treatments.[29] More importantly, in our strategy, both the apoptosis evaluation assay and phagocytosis assay indicated that the involvement of CD47 antibody enables CGs to regulate the phagocytosis of cancer cells rather than directly killing them at the nanomolar level.